Intricon Reports Third Quarter 2020 Results

Rhea-AI Summary

Intricon Corporation reported a solid performance for Q3 2020, achieving revenues of $27.4 million, a slight increase from $26.9 million year-over-year. The medical segment, bolstered by the acquisition of Emerald Medical Services, saw revenue rise to $20.6 million. However, diabetes revenue fell by 7.7%, while hearing health revenue dropped from $6.4 million to $5.5 million attributed to restructuring efforts. Gross margin improved to 26.3% from 25.2% and the company reported a net income of $0.6 million, or $0.07 per diluted share, compared to a loss last year.

Positive

• Revenue growth of $27.4 million, up from $26.9 million year-over-year.
• Medical segment revenue increases to $20.6 million, driven by the Emerald Medical Services acquisition.
• Improved gross margin of 26.3% versus 25.2% in Q3 2019.
• Net income of $0.6 million or $0.07 per diluted share contrasts with prior year loss.

Negative

• Diabetes revenue decline of 7.7% year-over-year.
• Hearing Health revenue decreased from $6.4 million to $5.5 million due to restructuring.

ARDEN HILLS, Minn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering and manufacturing miniature interventional, implantable and body-worn medical devices, today announced financial results for its third quarter ended September 30, 2020.

"Third quarter results included both year-over-year and sequential revenue growth as we see improvement across all our target medical markets. Continued emphasis on expense control while leveraging our core competencies to enter new medical markets for long-term growth remains a priority," said Scott Longval, President and Chief Executive Officer. "Our acquisition of Emerald Medical Services earlier this year is already demonstrating a meaningful contribution, while our directed focus on partnerships with innovators entering the emerging hearing health market is gaining traction." 

Third Quarter Highlights:
• Revenue of $27.4 million compared to $26.9 million in the prior year

• Diabetes revenue declined 7.7% year-over-year
• Other medical revenue increased 81.6% year-over-year, which included the contribution from recently acquired Emerald Medical Services

• Gross margin of 26.3%, compared to 25.2% in the prior year period
• Net income per diluted share of $0.07 versus net loss of $0.03 per diluted share in the prior year period

Third Quarter 2020 Financial Results
For the 2020 third quarter, the company reported net revenue of $27.4 million versus $26.9 million in the comparable prior-year period.

Revenue in Intricon’s Medical business was $20.6 million, an increase from $19.1 million in the comparable prior-year period. The year-over-year increase was driven primarily by our medical coils business and the impact of Emerald Medical Services which the company acquired in May 2020, partially offset by the reduction in orders due to uncertainty surrounding the COVID-19 pandemic.

Hearing Health revenue was $5.5 million in the third quarter of 2020 compared to $6.4 million in the prior-year third quarter. The revenue decline during the third quarter was largely attributed to the absence of hi Health Innovations revenue and a reduction in advertising as part of the Hearing Help Express restructuring efforts.

Gross margin in the third quarter of 2020 was 26.3%, compared to 25.2% in the prior-year third quarter, primarily due to the cost reduction initiatives and higher volumes.

Operating expenses for the third quarter were $6.7 million, compared to $7.2 million in the comparable prior-year period. The change in operating expenses year over year was due to the cost reduction initiatives.

The company posted a net income of $0.6 million or $0.07 per diluted share in the third quarter of 2020, versus net loss of $0.3 million or $0.03 per diluted share, for the 2019 third quarter.

Conference Call
Intricon will hold a conference call today, November 9, 2020, beginning at 4:00 p.m. CT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 866-795-7248 for domestic callers or 470-495-9160 for international callers, using conference ID: 6348919. A live and archived webcast will be available on the “Investors” sections of the company’s website at: www.Intricon.com.

Forward-Looking Statements
Statements made in this release and in Intricon’s other public filings and releases that are not historical facts or that include forward-looking terminology, including estimates of future results, the impact of the Emerald acquisition, statements regarding the estimated costs and expenses of the restructuring and estimated annual expense savings, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be affected by known and unknown risks, uncertainties and other factors that are beyond Intricon’s control, including without limitation, the impacts of the COVID-19 pandemic and measures taken in response, the risks associated with the Emerald acquisition, , and may cause Intricon’s actual results, performance or achievements to differ materially from the results, performance and achievements expressed or implied in the forward-looking statements. These risks, uncertainties and other factors are detailed from time to time in the company’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2019 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. The company disclaims any intent or obligation to publicly update or revise any forward-looking statements, regardless of whether new information becomes available, future developments occur or otherwise.

About Intricon Corporation
Headquartered in Arden Hills, Minn., Intricon Corporation designs, develops and manufactures miniature interventional, implantable and body-worn devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better-connected devices. Intricon has facilities in the United States, Asia, and Europe. The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market. For more information about Intricon, visit www.intricon.com.

Investor Contact
Leigh Salvo
(415) 937-5404 
investorrelations@intricon.com

INTRICON CORPORATION
MARKET REVENUE
(Unaudited)

	THIRD QUARTER									YEAR TO DATE
($ in 000's)	2020			2019			Change			2020			2019			Change
Medical	$	20,649		$	19,099		8.1	%		$	55,125		$	60,784		-9.3	%
Diabetes		14,518			15,723		-7.7	%			41,569			50,837		-18.2	%
Other Medical		6,131			3,376		81.6	%			13,556			9,947		36.3	%
Hearing Health		5,491			6,358		-13.6	%			13,845			20,044		-30.9	%
Value Based Direct-to-End-Consumer		953			1,510		-36.9	%			3,513			4,876		-28.0	%
Value Based Indirect-to-End-Consumer		1,779			2,443		-27.2	%			3,888			7,419		-47.6	%
Legacy OEM		2,759			2,405		14.7	%			6,444			7,749		-16.8	%
Professional Audio Communications		1,227			1,436		-14.6	%			3,502			4,972		-29.6	%
Total	$	27,367		$	26,893		1.8	%		$	72,472		$	85,800		-15.5	%

INTRICON CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Amounts)

		Three Months Ended							Nine Months Ended
(unaudited)		September 30,			September 30,				September 30,				September 30,
		2020			2019				2020				2019
Revenue, net	$	27,367		$	26,893			$	72,472			$	85,800
Cost of goods sold		20,169			20,120				54,096				62,253
Gross profit		7,198			6,773				18,376				23,547
Operating expenses:
Sales and marketing		1,365			2,609				5,038				9,071
General and administrative		3,654			3,715				11,673				10,551
Research and development		1,458			840				3,868				2,902
Restructuring charges		-			-				1,171				-
Impairment loss		-			-				-				3,765
Other operating expenses		253			-				746				-
Total operating expenses		6,730			7,164				22,496				26,289
Operating income (loss)		468			(391	)			(4,120	)			(2,742	)
Interest income, net		41			240				322				703
Other income (expense), net		192			(52	)			293				(458	)
Income (loss) from continuing operations before income taxes and discontinued operations		701			(203	)			(3,505	)			(2,497	)
Income tax expense		47			87				94				334
Income (loss) from continuing operations before discontinued operations		654			(290	)			(3,599	)			(2,831	)
Loss on disposal of discontinued operations		-			-				-				(1,116	)
Loss from discontinued operations		-			-				-				(597	)
Net income (loss)		654			(290	)			(3,599	)			(4,544	)
Less: Income allocated to non-controlling interest		10			-				17				-
Net income (loss) attributable to IntriCon shareholders	$	644		$	(290	)		$	(3,616	)		$	(4,544	)
Basic income (loss) per share attributable to IntriCon shareholders:
Continuing operations	$	0.07		$	(0.03	)		$	(0.41	)		$	(0.32	)
Discontinued operations		-			-				-				(0.20	)
Net income (loss) per share:	$	0.07		$	(0.03	)		$	(0.41	)		$	(0.52	)
Diluted income (loss) per share attributable to IntriCon shareholders:
Continuing operations	$	0.07		$	(0.03	)		$	(0.41	)		$	(0.32	)
Discontinued operations		-			-				-				(0.20	)
Net income (loss) per share:	$	0.07		$	(0.03	)		$	(0.41	)		$	(0.52	)
Average shares outstanding:
Basic		8,936			8,764				8,877				8,738
Diluted		9,272			8,764				8,877				8,738

INTRICON CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEET
(In Thousands, Except Share Amounts)

(unaudited)		September 30,				December 31,
		2020				2019
Current assets:
Cash and cash equivalents	$	16,081			$	8,523
Restricted cash		647				639
Short-term investment securities		14,176				23,451
Accounts receivable, less provision for doubtful accounts of $365 at September 30, 2020 and $325 at December 31, 2019		9,192				8,993
Inventories		20,463				16,377
Contract assets		10,592				10,237
Other current assets		1,426				1,975
Current assets of discontinued operations		-				80
Total current assets		72,577				70,275
Machinery and equipment		45,083				41,073
Less: Accumulated depreciation		30,915				27,522
Net machinery and equipment		14,168				13,551
Goodwill		13,714				9,551
Intangible assets		11,282				5,545
Operating lease right-of-use assets, net		3,812				4,372
Investment in partnerships		623				1,160
Long-term investment securities		-				8,629
Other assets, net		289				510
Total assets	$	116,465			$	113,593
Current liabilities:
Current financing leases	$	34			$	101
Current operating leases		1,512				1,729
Accounts payable		8,340				9,876
Accrued salaries, wages and commissions		4,271				2,274
Other accrued liabilities		4,429				2,869
Liabilities of discontinued operations		-				77
Total current liabilities		18,586				16,926
Noncurrent financing leases		2				30
Noncurrent operating leases		2,475				2,937
Other postretirement benefit obligations		349				382
Accrued pension liabilities		667				655
Deferred tax liabilities, net		1,104				-
Other long-term liabilities		3,790				2,171
Total liabilities		26,973				23,101
Commitments and contingencies
Shareholders’ equity:
Common stock, $1.00 par value per share; 20,000 shares authorized; 8,943 and 8,781 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		8,943				8,781
Additional paid-in capital		88,908				86,770
Accumulated deficit		(7,902	)			(4,286	)
Accumulated other comprehensive loss		(474	)			(520	)
Total shareholders' equity		89,475				90,745
Non-controlling interest		17				(253	)
Total equity		89,492				90,492
Total liabilities and equity	$	116,465			$	113,593

FAQ

What were Intricon Corporation's revenue figures for Q3 2020?

Intricon Corporation reported revenues of $27.4 million for Q3 2020, up from $26.9 million in Q3 2019.

How did the acquisition of Emerald Medical Services affect Intricon's finances?

The acquisition of Emerald Medical Services contributed to a revenue increase in Intricon's medical segment, which reached $20.6 million.

What was the net income for Intricon Corporation in Q3 2020?

Intricon Corporation posted a net income of $0.6 million, or $0.07 per diluted share for Q3 2020.

How did COVID-19 impact Intricon's diabetes revenue?

Diabetes revenue declined by 7.7% year-over-year due to uncertainty surrounding the COVID-19 pandemic.

What was the gross margin reported by Intricon for the third quarter?

Intricon reported a gross margin of 26.3% for Q3 2020, improved from 25.2% in the prior year.